Interdisciplinary Conference on Tobacco Regulation and E-cigarette Control

Events by 2FIRSTS.ai
Nov.23.2023
Interdisciplinary Conference on Tobacco Regulation and E-cigarette Control
Brazil to hold its first interdisciplinary conference, the "SBGMD," on November 25 in Guarujá to discuss tobacco regulation and e-cigarette impact.

Brazil will hold its first interdisciplinary conference on November 25th, Saturday, called the "SBGMD". The conference will take place in Guarujá and will address all aspects of tobacco use regulation, including issues concerning the suboptimal health population and smoking cessation efforts.

 

Doctors and scientists will discuss at the conference the impact of e-cigarette use on health and methods of controlling this practice.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report|FDA Revises Device Name in Glas Vape Authorization; Company Signals Optimism on Menthol, Flavored Pods
Special Report|FDA Revises Device Name in Glas Vape Authorization; Company Signals Optimism on Menthol, Flavored Pods
The FDA updated public records on the PMTA authorization of a Glas vape product, renaming “Glas G Device” to “Glas G² Device” and releasing the order letter detailing scientific review and marketing restrictions. Company disclosures suggest the platform may include age-verification technology. If confirmed, Glas G² could be the first vape with device-level age verification to receive an FDA MGO. Glas executives also said menthol and other flavored pods could gain authorization in the future.
Special Report
Mar.14
Turkey’s New Tobacco Bill Draft Would Cover E-Cigarettes and Heated Tobacco Products
Turkey’s New Tobacco Bill Draft Would Cover E-Cigarettes and Heated Tobacco Products
A Turkey’s draft would impose major limits on the use of tobacco products in public buildings, educational and healthcare institutions, children’s areas, and outdoor events, while setting a 2040 target for a complete ban on the production, sale, and consumption of tobacco products. The draft also broadens the definition of tobacco products to include e-cigarettes, heated tobacco products, and all nicotine-containing systems.
Apr.13 by 2FIRSTS.ai
FDA Wins Default Entry in Case Against E-Cigarette Distributor, to Seek Permanent Injunction
FDA Wins Default Entry in Case Against E-Cigarette Distributor, to Seek Permanent Injunction
The U.S. Food and Drug Administration (FDA) has made procedural progress in its lawsuit against North Carolina-based e-cigarette distributor Dream Distro LLC and its owner. A federal district judge granted the government’s request for entry of default after the defendants failed to respond to the complaint within 21 days of service. The government will next seek a default judgment, including a permanent injunction.
Apr.09 by 2FIRSTS.ai
Exclusive: Glas says FDA-authorized G2 vape includes age-gating technology
Exclusive: Glas says FDA-authorized G2 vape includes age-gating technology
Glas has confirmed to 2Firsts that its G2 device, which received a FDA Marketing Granted Order (MGO), incorporates age-gating technology. Based on currently public information, this means the FDA has granted an MGO to the first ENDS product confirmed to incorporate age-gating technology, validating 2Firsts’ earlier inference.
Mar.17
Haypp Reports 15% Q4 Sales Growth as Nicotine Pouch Volumes Rise
Haypp Reports 15% Q4 Sales Growth as Nicotine Pouch Volumes Rise
Haypp Group announced that net sales for October–December 2025 rose 15% year-on-year to SEK 1,052.2 million, or 19% in constant currency terms. The company recorded 28% volume growth in the nicotine pouch category during the quarter. The number of orders increased to 1.34 million, and active consumers rose to 630,000, marking the highest level in the company’s history. CEO Gavin O’Dowd said the company’s accelerating topline performance in the US and UK positions it for a strong 2026.
Market
Feb.22
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai